Copy
NOhep News - your monthly bulletin from the global movement to eliminate viral hepatitis.
Read this email in your browser
Hello NOhep Activists!

Welcome to NOhep News, your monthly bulletin from the global movement to eliminate viral hepatitis!

This month, we are excited to highlight the inspirational NOhep initiatives that you have spearheaded across Europe, Africa and South Asia. We've also covered three major news stories from around the world that have affected the NOhep community.

Keep scrolling to get inspired!

The NOhep Team
Egypt ➔
A historic 'anti-hepatitis' drive has launched in Egypt, aiming to target more than 50 million people in 7 months.

Brazil ➔
Cheaper generics? A Brazilian court has stripped Gilead of patent protection on a big-selling hepatitis C treatment.

UK ➔
As inquiries began this month, the Infected Blood Inquiry gained widespread media attention.
 
NOhep Community ➔
Macedonia. Uganda. Scotland. Pakistan. Discover inspirational NOhep initiatives currently taking place across the globe!

Supporter Spotlight ➔
How Ammal Metwally has driven action to eliminate viral hepatitis in villages throughout Egypt.
 
Natural disasters and other external factors threaten elimination efforts. What can NOhep do to ensure its prioritisation?

"A model for the world"
The first of three stages in a 'historic' anti-hepatitis drive in Egypt launched this month. What will it mean for elimination?

Egypt has launched a new initiative to target hepatitis C in the country, with the goal of being free from hepatitis C by 2020. Under the initiative, 50 million Egyptians will be targeted.

Egypt currently suffers from high rates of hepatitis infection; to combat this, the programme will offer screenings at state hospitals, medical centres, mobile clinics and youth centres, with those testing positive for hepatitis C being treated for free.


Read about Ammal Metwally's work to eliminate viral hepatitis in Egypt via the NOhep website.

"Extremely encouraging"
The ruling of a Brazilian court will have major implications for 700,000 Brazilians who cannot afford access to hepatitis C treatment.

A Brazilian court has stripped Gilead Sciences, a major US pharmaceutical company, of its exclusivity patent for the hepatitis C drug sofosbuvir.

The drug, which Gilead held under the brand name Sovaldi, is an extremely effective, orally administered treatment for hepatitis C. The court's ruling has opened up the possibility that Brazilian companies might provide a cheaper, generic version of sofosbuvir


 Read in full via Médecins Sans Frontières, September 26 2018.

Above: Health experts, MSPs and charities gathered in Edinburgh to widen access to hepatitis C treatment in Scotland
Left: Community outreach in Bugembe Budumbuli, Uganda, where citizens could access HIV testing and counselling as well as Hepatitis B Screening.
Right: Hepar Centar Bitola provide a NOhep presence at Macdeonia's Pink Walk for Breast Cancer.

NOhep is a global movement to unite people from across the world behind one common purpose: the elimination of viral hepatitis.






This email was sent to <<EMAIL>>
why did I get this?    unsubscribe from this list    update subscription preferences
NOhep · 27 Crosby Row · London, London SE1 3YD · United Kingdom